Methods for enhancing efficacy of therapeutic immune cells

Abstract

Abstract The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor - CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof. This data, for application number 2022204601, is current as of 2025-07-03 09:06 AEST Abstract The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor - CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof. This data, for application number 2022204601, is current as of 2025-07-03 09:06 AEST 20 25 20 50 77 03 J ul 2 02 5 A b s t r a c t T h e p r e s e n t i n v e n t i o n r e l a t e s t o a m e t h o d o f u s i n g a r e c e p t o r ( e . g . , c h i m e r i c a n t i g e n r e c e p t o r - C A R ) t h a t a c t i v a t e s a n i m m u n e r e s p o n s e u p o n b i n d i n g a c a n c e r c e l l l i g a n d i n c o n j u n c t i o n w i t h a t a r g e t - b i n d i n g 2 0 2 5 2 0 5 0 7 7 0 3 J u l 2 0 2 5 m o l e c u l e t h a t t a r g e t s a p r o t e i n o r m o l e c u l e f o r r e m o v a l o r n e u t r a l i z a t i o n t o g e n e r a t e e n h a n c e d a n t i - c a n c e r i m m u n e c e l l s . T h e p r e s e n t i n v e n t i o n a l s o r e l a t e s t o e n g i n e e r e d i m m u n e c e l l s h a v i n g e n h a n c e d t h e r a p e u t i c e f f i c a c y a n d u s e s t h e r e o f . T h i s d a t a , f o r a p p l i c a t i o n n u m b e r 2 0 2 2 2 0 4 6 0 1 , i s c u r r e n t a s o f 2 0 2 5 - 0 7 - 0 3 0 9 : 0 6 A E S T 2 0 2 5 2 0 5 0 7 7 0 3 J u l 2 0 2 5 This data, for application number 2025205077, is current as of 2026-09-23 11:41 AEST 2025205077 03 Jul 2025 20 26 23 80 43 23 S ep 2 02 6 2 0 0 2 6 2 3 8 0 4 6 7 2 0 3 S l e p 2 0 2 6

Images